Ana Castro

Ana Castro

Auto-generated profile, based on publicly available information

Ana Castro

Centro Hospitalar do Porto, Hospital de Santo António, Departamente de Nefrologia, Porto, Portugal

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2018 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
ACAna Coutinho Castro
Ana Coutinho Castro
MNMauro Neri
Mauro Neri
AKAkash Nayak Karopadi
Akash Nayak Karopadi
ALAnna Lorenzin
Anna Lorenzin
NMNicola Marchionna
Nicola Marchionna
CRClaudio Ronco
Claudio Ronco
Since 2005, three human clinical trials have been performed with the Wearable Artificial Kidney (WAK) and Wearable Ultrafiltration (WUF) device. The lack of an adequate vascular access (VA) has been pointed out as the main limitation to their implementation. Based on the current level of understanding, we will make the first conceptual proposal of an adequate VA suitable for the WAK and the WUF. All the literature related to WAK and WUF was reviewed. Based on eight main publications the VA major characteristics were defined: a mean blood flow of 100 mL/min; the capability to allow prolonged and frequent dialysis treatments, without interfering in activities of daily living (ADL); safe and convenient connection/disconnection systems; reduced risk of biofilm formation and coagulation; high biocompatibility. A research was done in order to answer to each necessary technological prerequisites. The use of a device similar to a CVC with a 5Fr lumen, seems to be the most feasible option. Totally subcutaneous port devices, like the LifeSite(R) or Dialock (R) systems can be a solution to allow WAK or WUF to operate continuously while patients carry out their ADL. Recently, macromolecules that reduce the risk of thrombosis and infection and are integrated into a CVC have been developed and have the capability of overcoming these major limitations. With an adequate VA, portable HD devices can be acceptable options to address several unmet clinical needs of HD patients.

11 November 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FFFiorenza Ferrari
Fiorenza Ferrari
GRGregorio Romero-González
Gregorio Romero-González
LTLilia Rizo Topete
Lilia Rizo Topete
MSMara Senzolo
Mara Senzolo
ALAnna Lorenzin
Anna Lorenzin
CRClaudio Ronco
Claudio Ronco
The urinary tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 ([TIMP-2]∙[IGFBP7]) have been introduced to improve risk prediction of severe acute kidney injury (AKI) within 12 hours of measurement. We performed a prospective cohort study to evaluate if the predictive value of [TIMP-2]∙[IGFBP7] for AKI might continue after 12 hours. We enrolled 442 critically ill adult patients from June to December 2016. Urine samples were collected at admission for [TIMP-2]∙[IGFBP7] measurement. Baseline patient characteristics were recorded including patients’ demographics, prior health history, and the main reason for admission to build a logistic regression model to predict AKI. AKI occurrence differed between patients with [TIMP-2]∙[IGFBP7] ≤0.3 and >0.3 (ng/ml)2/1000 (31.9% and 68.10% respectively; p < 0.001). Patients with AKI had higher biomarker values compared to those without AKI (0.66 (0.21–2.84) vs 0.22 (0.08–0.63) (ng/ml)2/1000; p < 0.001). [TIMP-2]∙[IGFBP7] at ICU admission had a lower performance in predicting AKI at any stage within 48 hours and 7 days after measurement (area under the receiver operating characteristic curve (AUC) equal to 0.70 (95%CI 0.65–0.76), AUC 0.68 (95%CI 0.63–0.73)). In the logistic regression model, 0.1 (ng/ml)2/1000-unit increment was likely to increase the risk of AKI by 2% (p = 0.002).

20 June 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FFFiorenza Ferrari
Fiorenza Ferrari
MPMariangela Puci
Mariangela Puci
Ottavia Eleonora FerraroOttavia Eleonora Ferraro
Ottavia Eleonora Ferraro
GRGregorio Romero-González
Gregorio Romero-González
FHFaeq Husain-Syed
Faeq Husain-Syed
CRClaudio Ronco
Claudio Ronco
AKI is associated with increased risk of death, prolonged length of stay and development of de-novo chronic kidney disease. The aim of our study is the development and validation of prediction models to identify the risk of AKI in ICU patients up to 7 days. We retrospectively recruited 692 consecutive patients admitted to the ICU at San Bortolo Hospital (Vicenza, Italy) from 1 June 2016 to 31 March 2017: 455 patients were treated as the derivation group and 237 as the validation group. Candidate variables were selected based on a literature review and expert opinion. Admission eGFR< 90 ml/min /1.73 mq (OR 2.78; 95% CI 1.78–4.35; p<0.001); SOFAcv ≥ 2 (OR 2.23; 95% CI 1.48–3.37; p<0.001); lactate ≥ 2 mmol/L (OR 1.81; 95% CI 1.19–2.74; p = 0.005) and (TIMP-2)•(IGFBP7) ≥ 0.3 (OR 1.65; 95% CI 1.08–2.52; p = 0.019) were significantly associated with AKI. For the q-AKI score, we stratified patients into different AKI Risk score levels: 0–2; 3–4; 5–6; 7–8 and 9–10. In both cohorts, we observed that the proportion of AKI patients was higher in the higher score levels.

24 August 2017 in HLA
Verified
Journal Article
Closed access
PDF file
ACA. Castro
A. Castro
JMJorge Malheiro
Jorge Malheiro
STSandra Tafulo
Sandra Tafulo
LDL. Dias
L. Dias
LMLa Salete LA SALETE S Martins
La Salete LA SALETE S Martins
ACA. Cabrita
A. Cabrita

19 April 2018 in Blood Purification
Verified
Journal Article
Closed access
PDF file
ACAna Castro
Ana Castro
CMCarla Moreira
Carla Moreira
PAPaulo Almeida
Paulo Almeida
NMNorton de Matos
Norton de Matos
LLLuís Loureiro
Luís Loureiro
JQJosé Queirós
José Queirós
Background: The definition of significant stenosis (SS) remains controversial. Methods: We retrospectively reviewed 1,040 consultations. SS was defined in the presence of clinical and echo-Doppler (DDU) criteria: Qa 25%; RI >0.7 in the feeding artery or absolute minimal luminal stenosis diameter <2.0 mm. Stenosis without any additional criteria were considered borderline stenosis (BS). Results: Two hundred twenty-one arteriovenous fistulas (AVFs) were included: 58.8% had SS, 18.6% had BS, and 22.6% had no dysfunctional access (ND). SS had a significantly higher thrombotic events than BS and ND (13.1 vs. 4.4%, p = 0.018). The annual thrombosis rate was 0.007, 0.037, and 0.004 in the ND, SS, and BS, respectively. AVF cumulative survival at 5 years was significantly lower in SS (89.5%) compared to BS (100%) and ND (97.4%; p = 0.03). BS had an HR for AVF failure of 1.1, p = 0.955, while the SS presented an HR of 5.9, p = 0.09. Conclusion: AVF clinical monitoring with additional DDU criteria appear to be appropriate for therapeutic referral.

1 February 2019 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
CMCarla Leal Moreira
Carla Leal Moreira
ACAna Castro
Ana Castro
FSFernanda Silva
Fernanda Silva
PAPaulo Almeida
Paulo Almeida
AMAntónio Nórton de Matos
António Nórton de Matos
JQJosé Alexandre Queirós
José Alexandre Queirós